C-REGS2 - A Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients With Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke
Phase of Trial: Phase IV
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs Brain extract (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms C-REGS2
- Sponsors EVER Neuro Pharma
- 14 Oct 2019 Planned End Date changed from 30 Mar 2021 to 30 May 2021.
- 14 Oct 2019 Planned primary completion date changed from 30 Sep 2020 to 30 Nov 2020.
- 06 Feb 2019 Planned End Date changed from 30 Sep 2020 to 30 Mar 2021.